The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01792388
Recruitment Status :
First Posted : February 15, 2013
Last Update Posted : July 22, 2014
University of Dublin, Trinity College
University of Calgary
Queen Mary University of London
Information provided by (Responsible Party):
Tara Raftery, University of Dublin, Trinity College
Increased Intestinal Permeability is detectable in clinically active Crohn's disease, in stable Crohn's disease and is predictive of clinical relapse. Maintenance of the epithelial barrier integrity is therefore essential for intestinal homeostasis. Vitamin D may have a critical role in improving barrier function.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
All patients must fulfill the clinical criteria for diagnosis of CD as defined by Lennard-Jones et al. (1976)
All patients must be in clinical remission for at least 1 month at study entry as defined by a Crohn's Disease Activity Index (CDAI) of <150
Patients on stable drug therapies for at least 1 month pre-enrolment
Sufficient English language ability to carry out the study requirements
Symptomatic CD at study entry including CDAI >150
Previous extensive small bowel resection (less than 200 cm of viable small bowel or a loss of 50% or more of the small intestine)